Pregnancy Cat

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Brexpiprazole during pregnancy. Lactation studies have not been conducted to assess the presence of brexpiprazole in human milk, the effects of brexpiprazole on the breastfed infant, or the effects of brexpiprazole on milk production. Brexpiprazole is present in rat milk. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Brexpiprazole and any potential adverse effects on the breastfed infant from Brexpiprazole or from the underlying maternal condition.

Precautions

Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-

Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack)
Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring
Tardive Dyskinesia: Discontinue if clinically appropriate
Metabolic Changes: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia and weight gain
Pathological Gambling and Other Compulsive Behaviors: Consider dose reduction or discontinuation
Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Consider discontinuing Brexpiprazole if a clinically significant decline in WBC occurs in absence of other causative factors
Orthostatic Hypotension and Syncope: Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope
Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold

Overdose Effects

n/a

Drug Classes

Benzodiazepine antagonist

Storage Conditions

Do not store above 30°C temperature. Keep away from light & wet place. Keep out of reach of children.

Composition

n/a

Mode Of Action

Brexpiprazole is an atypical antipsychotic agent. The pharmacology of Brexpiprazole is believed to be mediated by a modulatory activity at the serotonin and dopamine systems that combines partial agonist activity at serotonergic 5-HT1A and at dopaminergic D2 receptors with antagonist activity at serotonergic 5-HT2A receptors. It shows similar high affinities at all of these receptors. Brexpiprazole also shows antagonist activity at noradrenergic a1B/2c receptors.

Reconstitution

n/a